Public Health England, in partnership with the University of Oxford, recently conducted a head-to-head evaluation of four commercial immunoassay tests used for the detection of SARS-CoV-2 antibodies. The laboratory-based total antibody test COV2T, from Siemens Healthineers, Erlangen, Germany, was the only assay of the four found to meet both the sensitivity and specificity requirements set out in the target product profile for enzyme immunoassays by the UK Medicines and Healthcare products Regulatory Agency.
“High-quality antibody tests will be critical to successfully reopening economies across the globe. From the start, our mission has been to develop highly accurate tests for SARS-CoV-2 and now we have an external appraisal that confirms our test offers exceptional quality,” says Deepak Nath, PhD, president of laboratory diagnostics at Siemens Healthineers. “Laboratories worldwide can be confident that our assay delivers the sensitivity and specificity we promised.”
The COV2T is CE marked and has FDA emergency use authorization. The test detects the presence of both IgM and IgG antibodies in blood.
For more information, visit Siemens Healthineers.